nodes	percent_of_prediction	percent_of_DWPC	metapath
Mifepristone—ABCB1—Topotecan—cervical cancer	0.384	0.625	CbGbCtD
Mifepristone—CYP3A4—Topotecan—cervical cancer	0.23	0.375	CbGbCtD
Mifepristone—AR—semen—cervical cancer	0.0335	0.123	CbGeAlD
Mifepristone—PGR—epithelium—cervical cancer	0.00775	0.0285	CbGeAlD
Mifepristone—PGR—uterine cervix—cervical cancer	0.00768	0.0283	CbGeAlD
Mifepristone—PGR—decidua—cervical cancer	0.00732	0.027	CbGeAlD
Mifepristone—PGR—endometrium—cervical cancer	0.00695	0.0256	CbGeAlD
Mifepristone—PGR—uterus—cervical cancer	0.0064	0.0236	CbGeAlD
Mifepristone—AR—epithelium—cervical cancer	0.00617	0.0227	CbGeAlD
Mifepristone—AR—uterine cervix—cervical cancer	0.00612	0.0225	CbGeAlD
Mifepristone—AR—decidua—cervical cancer	0.00583	0.0215	CbGeAlD
Mifepristone—ABCC1—uterine cervix—cervical cancer	0.00581	0.0214	CbGeAlD
Mifepristone—PGR—female reproductive system—cervical cancer	0.00576	0.0212	CbGeAlD
Mifepristone—AR—renal system—cervical cancer	0.00573	0.0211	CbGeAlD
Mifepristone—Rash maculo-papular—Topotecan—cervical cancer	0.00565	0.0555	CcSEcCtD
Mifepristone—ABCC1—decidua—cervical cancer	0.00554	0.0204	CbGeAlD
Mifepristone—AR—endometrium—cervical cancer	0.00554	0.0204	CbGeAlD
Mifepristone—AR—mammalian vulva—cervical cancer	0.00536	0.0197	CbGeAlD
Mifepristone—ABCC1—endometrium—cervical cancer	0.00526	0.0194	CbGeAlD
Mifepristone—PGR—female gonad—cervical cancer	0.00524	0.0193	CbGeAlD
Mifepristone—PGR—vagina—cervical cancer	0.00521	0.0192	CbGeAlD
Mifepristone—AR—uterus—cervical cancer	0.0051	0.0188	CbGeAlD
Mifepristone—ABCC1—mammalian vulva—cervical cancer	0.00509	0.0187	CbGeAlD
Mifepristone—ABCC1—uterus—cervical cancer	0.00485	0.0178	CbGeAlD
Mifepristone—AR—female reproductive system—cervical cancer	0.00459	0.0169	CbGeAlD
Mifepristone—NR3C1—epithelium—cervical cancer	0.00447	0.0165	CbGeAlD
Mifepristone—CYP3A5—uterine cervix—cervical cancer	0.00447	0.0165	CbGeAlD
Mifepristone—NR3C1—uterine cervix—cervical cancer	0.00443	0.0163	CbGeAlD
Mifepristone—NR3C1—decidua—cervical cancer	0.00422	0.0156	CbGeAlD
Mifepristone—CYP3A5—renal system—cervical cancer	0.00418	0.0154	CbGeAlD
Mifepristone—AR—female gonad—cervical cancer	0.00417	0.0154	CbGeAlD
Mifepristone—AR—vagina—cervical cancer	0.00415	0.0153	CbGeAlD
Mifepristone—NR3C1—renal system—cervical cancer	0.00415	0.0153	CbGeAlD
Mifepristone—Cramp muscle—Topotecan—cervical cancer	0.00406	0.0399	CcSEcCtD
Mifepristone—NR3C1—endometrium—cervical cancer	0.00401	0.0148	CbGeAlD
Mifepristone—ABCC1—female gonad—cervical cancer	0.00396	0.0146	CbGeAlD
Mifepristone—ABCC1—vagina—cervical cancer	0.00394	0.0145	CbGeAlD
Mifepristone—NR3C1—mammalian vulva—cervical cancer	0.00388	0.0143	CbGeAlD
Mifepristone—NR3C1—uterus—cervical cancer	0.0037	0.0136	CbGeAlD
Mifepristone—Infestation—Topotecan—cervical cancer	0.00348	0.0342	CcSEcCtD
Mifepristone—Infestation NOS—Topotecan—cervical cancer	0.00348	0.0342	CcSEcCtD
Mifepristone—PGR—lymph node—cervical cancer	0.00337	0.0124	CbGeAlD
Mifepristone—NR3C1—female reproductive system—cervical cancer	0.00332	0.0122	CbGeAlD
Mifepristone—CYP3A4—renal system—cervical cancer	0.00314	0.0116	CbGeAlD
Mifepristone—Haemoglobin—Topotecan—cervical cancer	0.00314	0.0308	CcSEcCtD
Mifepristone—Haemorrhage—Topotecan—cervical cancer	0.00312	0.0307	CcSEcCtD
Mifepristone—CYP2D6—renal system—cervical cancer	0.00309	0.0114	CbGeAlD
Mifepristone—CYP3A5—female gonad—cervical cancer	0.00305	0.0112	CbGeAlD
Mifepristone—CYP3A5—vagina—cervical cancer	0.00303	0.0112	CbGeAlD
Mifepristone—NR3C1—female gonad—cervical cancer	0.00302	0.0111	CbGeAlD
Mifepristone—NR3C1—vagina—cervical cancer	0.003	0.0111	CbGeAlD
Mifepristone—Angiopathy—Topotecan—cervical cancer	0.00283	0.0278	CcSEcCtD
Mifepristone—Mediastinal disorder—Topotecan—cervical cancer	0.00281	0.0276	CcSEcCtD
Mifepristone—Chills—Topotecan—cervical cancer	0.0028	0.0275	CcSEcCtD
Mifepristone—Malnutrition—Topotecan—cervical cancer	0.00272	0.0267	CcSEcCtD
Mifepristone—AR—lymph node—cervical cancer	0.00268	0.00988	CbGeAlD
Mifepristone—Back pain—Topotecan—cervical cancer	0.00263	0.0258	CcSEcCtD
Mifepristone—Muscle spasms—Topotecan—cervical cancer	0.00261	0.0257	CcSEcCtD
Mifepristone—ABCC1—lymph node—cervical cancer	0.00255	0.00939	CbGeAlD
Mifepristone—Ill-defined disorder—Topotecan—cervical cancer	0.00252	0.0248	CcSEcCtD
Mifepristone—CYP3A4—female reproductive system—cervical cancer	0.00251	0.00925	CbGeAlD
Mifepristone—Angioedema—Topotecan—cervical cancer	0.00248	0.0244	CcSEcCtD
Mifepristone—CYP2D6—female reproductive system—cervical cancer	0.00247	0.00911	CbGeAlD
Mifepristone—Malaise—Topotecan—cervical cancer	0.00245	0.0241	CcSEcCtD
Mifepristone—ABCB1—epithelium—cervical cancer	0.00239	0.00882	CbGeAlD
Mifepristone—ABCB1—uterine cervix—cervical cancer	0.00237	0.00874	CbGeAlD
Mifepristone—Myalgia—Topotecan—cervical cancer	0.00231	0.0227	CcSEcCtD
Mifepristone—Arthralgia—Topotecan—cervical cancer	0.00231	0.0227	CcSEcCtD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.0023	0.0226	CcSEcCtD
Mifepristone—Discomfort—Topotecan—cervical cancer	0.00229	0.0225	CcSEcCtD
Mifepristone—ABCB1—decidua—cervical cancer	0.00226	0.00833	CbGeAlD
Mifepristone—CYP2D6—female gonad—cervical cancer	0.00225	0.00829	CbGeAlD
Mifepristone—ABCB1—renal system—cervical cancer	0.00222	0.00818	CbGeAlD
Mifepristone—Infection—Topotecan—cervical cancer	0.0022	0.0216	CcSEcCtD
Mifepristone—Nervous system disorder—Topotecan—cervical cancer	0.00217	0.0214	CcSEcCtD
Mifepristone—Skin disorder—Topotecan—cervical cancer	0.00215	0.0212	CcSEcCtD
Mifepristone—ABCB1—endometrium—cervical cancer	0.00215	0.00791	CbGeAlD
Mifepristone—Anorexia—Topotecan—cervical cancer	0.00211	0.0208	CcSEcCtD
Mifepristone—ABCB1—mammalian vulva—cervical cancer	0.00208	0.00765	CbGeAlD
Mifepristone—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00202	0.0199	CcSEcCtD
Mifepristone—ABCB1—uterus—cervical cancer	0.00198	0.00729	CbGeAlD
Mifepristone—Dyspnoea—Topotecan—cervical cancer	0.00198	0.0194	CcSEcCtD
Mifepristone—NR3C1—lymph node—cervical cancer	0.00194	0.00716	CbGeAlD
Mifepristone—Decreased appetite—Topotecan—cervical cancer	0.00193	0.0189	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Topotecan—cervical cancer	0.00191	0.0188	CcSEcCtD
Mifepristone—Fatigue—Topotecan—cervical cancer	0.00191	0.0188	CcSEcCtD
Mifepristone—Pain—Topotecan—cervical cancer	0.0019	0.0186	CcSEcCtD
Mifepristone—Constipation—Topotecan—cervical cancer	0.0019	0.0186	CcSEcCtD
Mifepristone—Feeling abnormal—Topotecan—cervical cancer	0.00183	0.018	CcSEcCtD
Mifepristone—Gastrointestinal pain—Topotecan—cervical cancer	0.00181	0.0178	CcSEcCtD
Mifepristone—ABCB1—female reproductive system—cervical cancer	0.00178	0.00655	CbGeAlD
Mifepristone—Urticaria—Topotecan—cervical cancer	0.00176	0.0173	CcSEcCtD
Mifepristone—Body temperature increased—Topotecan—cervical cancer	0.00175	0.0172	CcSEcCtD
Mifepristone—Abdominal pain—Topotecan—cervical cancer	0.00175	0.0172	CcSEcCtD
Mifepristone—Hypersensitivity—Topotecan—cervical cancer	0.00163	0.0161	CcSEcCtD
Mifepristone—ABCB1—female gonad—cervical cancer	0.00162	0.00596	CbGeAlD
Mifepristone—ABCB1—vagina—cervical cancer	0.00161	0.00592	CbGeAlD
Mifepristone—Asthenia—Topotecan—cervical cancer	0.00159	0.0156	CcSEcCtD
Mifepristone—Pruritus—Topotecan—cervical cancer	0.00157	0.0154	CcSEcCtD
Mifepristone—Diarrhoea—Topotecan—cervical cancer	0.00152	0.0149	CcSEcCtD
Mifepristone—Dizziness—Topotecan—cervical cancer	0.00147	0.0144	CcSEcCtD
Mifepristone—Vomiting—Topotecan—cervical cancer	0.00141	0.0139	CcSEcCtD
Mifepristone—Rash—Topotecan—cervical cancer	0.0014	0.0137	CcSEcCtD
Mifepristone—Dermatitis—Topotecan—cervical cancer	0.0014	0.0137	CcSEcCtD
Mifepristone—Headache—Topotecan—cervical cancer	0.00139	0.0136	CcSEcCtD
Mifepristone—Nausea—Topotecan—cervical cancer	0.00132	0.0129	CcSEcCtD
Mifepristone—ABCB1—lymph node—cervical cancer	0.00104	0.00383	CbGeAlD
Mifepristone—PGR—Validated nuclear estrogen receptor alpha network—POU4F1—cervical cancer	0.000867	0.068	CbGpPWpGaD
Mifepristone—AR—Notch-mediated HES/HEY network—YY1—cervical cancer	0.000708	0.0556	CbGpPWpGaD
Mifepristone—PGR—Nuclear Receptors—RARB—cervical cancer	0.000691	0.0542	CbGpPWpGaD
Mifepristone—AR—Coregulation of Androgen receptor activity—PIAS3—cervical cancer	0.000686	0.0539	CbGpPWpGaD
Mifepristone—AR—Regulation of nuclear SMAD2/3 signaling—PIAS3—cervical cancer	0.000547	0.0429	CbGpPWpGaD
Mifepristone—PGR—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.000546	0.0429	CbGpPWpGaD
Mifepristone—AR—Nuclear Receptors—RARB—cervical cancer	0.000526	0.0413	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—PIAS3—cervical cancer	0.000507	0.0398	CbGpPWpGaD
Mifepristone—AR—Coregulation of Androgen receptor activity—UBE3A—cervical cancer	0.000442	0.0347	CbGpPWpGaD
Mifepristone—AR—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.000416	0.0327	CbGpPWpGaD
Mifepristone—NR3C1—Regulation of nuclear SMAD2/3 signaling—PIAS3—cervical cancer	0.000415	0.0326	CbGpPWpGaD
Mifepristone—NR3C1—Nuclear Receptors—RARB—cervical cancer	0.000399	0.0313	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—UBE3A—cervical cancer	0.000327	0.0257	CbGpPWpGaD
Mifepristone—NR3C1—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.000316	0.0248	CbGpPWpGaD
Mifepristone—AR—Notch-mediated HES/HEY network—HES1—cervical cancer	0.000241	0.0189	CbGpPWpGaD
Mifepristone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000235	0.0184	CbGpPWpGaD
Mifepristone—AR—Notch-mediated HES/HEY network—NOTCH1—cervical cancer	0.000182	0.0143	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.000162	0.0127	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.000145	0.0114	CbGpPWpGaD
Mifepristone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000144	0.0113	CbGpPWpGaD
Mifepristone—CYP3A4—Tryptophan metabolism—UBE3A—cervical cancer	0.000139	0.0109	CbGpPWpGaD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—cervical cancer	0.000138	0.0108	CbGpPWpGaD
Mifepristone—AR—Notch-mediated HES/HEY network—CD4—cervical cancer	0.000136	0.0107	CbGpPWpGaD
Mifepristone—AR—Coregulation of Androgen receptor activity—CASP8—cervical cancer	0.000135	0.0106	CbGpPWpGaD
Mifepristone—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cervical cancer	0.000111	0.00871	CbGpPWpGaD
Mifepristone—AR—Notch-mediated HES/HEY network—STAT3—cervical cancer	0.000105	0.00828	CbGpPWpGaD
Mifepristone—NR3C1—Endoderm Differentiation—NOTCH1—cervical cancer	0.000103	0.00807	CbGpPWpGaD
Mifepristone—PGR—Signaling by ERBB4—FGFR3—cervical cancer	9.95e-05	0.00781	CbGpPWpGaD
Mifepristone—AR—Coregulation of Androgen receptor activity—CTNNB1—cervical cancer	9.82e-05	0.00771	CbGpPWpGaD
Mifepristone—PGR—Generic Transcription Pathway—RARB—cervical cancer	9.43e-05	0.0074	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—HES1—cervical cancer	9.24e-05	0.00725	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—HLA-DPB1—cervical cancer	8.75e-05	0.00687	CbGpPWpGaD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—cervical cancer	7.9e-05	0.0062	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—CTNNB1—cervical cancer	7.26e-05	0.0057	CbGpPWpGaD
Mifepristone—AR—Generic Transcription Pathway—RARB—cervical cancer	7.19e-05	0.00564	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—HES1—cervical cancer	7.01e-05	0.0055	CbGpPWpGaD
Mifepristone—PGR—Signaling by ERBB4—MTOR—cervical cancer	7e-05	0.0055	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—HLA-DQB1—cervical cancer	6.83e-05	0.00536	CbGpPWpGaD
Mifepristone—NR3C1—Endoderm Differentiation—CTNNB1—cervical cancer	6.83e-05	0.00536	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—CTNNB1—cervical cancer	6.67e-05	0.00524	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—TERT—cervical cancer	6.56e-05	0.00515	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—CASP8—cervical cancer	6.52e-05	0.00512	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—STAT3—cervical cancer	6.33e-05	0.00497	CbGpPWpGaD
Mifepristone—PGR—Generic Transcription Pathway—NOTCH2—cervical cancer	6.25e-05	0.0049	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	5.9e-05	0.00463	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—EGFR—cervical cancer	5.75e-05	0.00451	CbGpPWpGaD
Mifepristone—NR3C1—Generic Transcription Pathway—RARB—cervical cancer	5.45e-05	0.00428	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	5.4e-05	0.00424	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—MTOR—cervical cancer	5.36e-05	0.00421	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—CASP3—cervical cancer	4.93e-05	0.00387	CbGpPWpGaD
Mifepristone—PGR—Signaling by ERBB4—EGFR—cervical cancer	4.92e-05	0.00386	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—CASP3—cervical cancer	4.81e-05	0.00377	CbGpPWpGaD
Mifepristone—AR—Generic Transcription Pathway—NOTCH2—cervical cancer	4.76e-05	0.00374	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	4.76e-05	0.00373	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—TAAR6—cervical cancer	4.71e-05	0.0037	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—CTNNB1—cervical cancer	4.63e-05	0.00364	CbGpPWpGaD
Mifepristone—PGR—Gene Expression—RARB—cervical cancer	4.54e-05	0.00356	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—CASP8—cervical cancer	4.46e-05	0.0035	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—TP53—cervical cancer	4.44e-05	0.00348	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	4.09e-05	0.00321	CbGpPWpGaD
Mifepristone—NR3C1—Adipogenesis—CTNNB1—cervical cancer	4.07e-05	0.00319	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	3.94e-05	0.00309	CbGpPWpGaD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—TP53—cervical cancer	3.91e-05	0.00307	CbGpPWpGaD
Mifepristone—PGR—Generic Transcription Pathway—NOTCH1—cervical cancer	3.87e-05	0.00304	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—EGFR—cervical cancer	3.77e-05	0.00296	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—WNT2—cervical cancer	3.68e-05	0.00289	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—CASP3—cervical cancer	3.65e-05	0.00286	CbGpPWpGaD
Mifepristone—NR3C1—Generic Transcription Pathway—NOTCH2—cervical cancer	3.61e-05	0.00283	CbGpPWpGaD
Mifepristone—NR3C1—Adipogenesis—STAT3—cervical cancer	3.54e-05	0.00278	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—CTNNB1—cervical cancer	3.51e-05	0.00276	CbGpPWpGaD
Mifepristone—AR—Gene Expression—RARB—cervical cancer	3.46e-05	0.00272	CbGpPWpGaD
Mifepristone—ABCC1—Disease—WNT2—cervical cancer	3.43e-05	0.00269	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—CASP3—cervical cancer	3.38e-05	0.00265	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—AKAP13—cervical cancer	3.23e-05	0.00253	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—TP53—cervical cancer	3.16e-05	0.00248	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	3.12e-05	0.00245	CbGpPWpGaD
Mifepristone—PGR—Gene Expression—NOTCH2—cervical cancer	3.01e-05	0.00236	CbGpPWpGaD
Mifepristone—AR—Generic Transcription Pathway—NOTCH1—cervical cancer	2.95e-05	0.00231	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—WNT5A—cervical cancer	2.79e-05	0.00219	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—CA9—cervical cancer	2.71e-05	0.00213	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—RARB—cervical cancer	2.62e-05	0.00206	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	2.62e-05	0.00206	CbGpPWpGaD
Mifepristone—ABCC1—Disease—WNT5A—cervical cancer	2.6e-05	0.00204	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—CA9—cervical cancer	2.36e-05	0.00186	CbGpPWpGaD
Mifepristone—AR—Gene Expression—NOTCH2—cervical cancer	2.29e-05	0.0018	CbGpPWpGaD
Mifepristone—NR3C1—Generic Transcription Pathway—NOTCH1—cervical cancer	2.24e-05	0.00175	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	2.2e-05	0.00173	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—NOTCH2—cervical cancer	1.96e-05	0.00153	CbGpPWpGaD
Mifepristone—PGR—Gene Expression—NOTCH1—cervical cancer	1.86e-05	0.00146	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—NOTCH2—cervical cancer	1.74e-05	0.00136	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—CA9—cervical cancer	1.71e-05	0.00134	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	1.67e-05	0.00131	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	1.61e-05	0.00126	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—HES1—cervical cancer	1.6e-05	0.00126	CbGpPWpGaD
Mifepristone—ABCC1—Disease—HES1—cervical cancer	1.49e-05	0.00117	CbGpPWpGaD
Mifepristone—AR—Gene Expression—NOTCH1—cervical cancer	1.42e-05	0.00111	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—TERT—cervical cancer	1.4e-05	0.0011	CbGpPWpGaD
Mifepristone—ABCC1—Disease—MTHFR—cervical cancer	1.31e-05	0.00103	CbGpPWpGaD
Mifepristone—ABCC1—Disease—TERT—cervical cancer	1.31e-05	0.00103	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—CA9—cervical cancer	1.29e-05	0.00101	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—FGFR3—cervical cancer	1.29e-05	0.00101	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	1.27e-05	0.000999	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—CA9—cervical cancer	1.22e-05	0.000954	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—NOTCH1—cervical cancer	1.21e-05	0.00095	CbGpPWpGaD
Mifepristone—ABCC1—Disease—FGFR3—cervical cancer	1.2e-05	0.000943	CbGpPWpGaD
Mifepristone—ABCC1—Disease—NOTCH1—cervical cancer	1.13e-05	0.000886	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—MTHFR—cervical cancer	1.1e-05	0.000863	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—NOTCH1—cervical cancer	1.08e-05	0.000845	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	1.07e-05	0.000838	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—MTHFR—cervical cancer	9.59e-06	0.000753	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—MTOR—cervical cancer	9.07e-06	0.000712	CbGpPWpGaD
Mifepristone—ABCC1—Disease—MTOR—cervical cancer	8.45e-06	0.000664	CbGpPWpGaD
Mifepristone—ABCC1—Disease—CD4—cervical cancer	8.44e-06	0.000662	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—CASP3—cervical cancer	8.34e-06	0.000655	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—CTNNB1—cervical cancer	8.04e-06	0.000631	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—CA9—cervical cancer	7.94e-06	0.000624	CbGpPWpGaD
Mifepristone—ABCC1—Disease—CTNNB1—cervical cancer	7.5e-06	0.000588	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—STAT3—cervical cancer	7.01e-06	0.00055	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—MTHFR—cervical cancer	6.93e-06	0.000544	CbGpPWpGaD
Mifepristone—ABCC1—Disease—STAT3—cervical cancer	6.53e-06	0.000513	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—EGFR—cervical cancer	6.37e-06	0.0005	CbGpPWpGaD
Mifepristone—ABCC1—Disease—EGFR—cervical cancer	5.94e-06	0.000466	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—TP53—cervical cancer	5.35e-06	0.00042	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—MTHFR—cervical cancer	5.23e-06	0.000411	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—MTHFR—cervical cancer	4.93e-06	0.000387	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—MTHFR—cervical cancer	3.22e-06	0.000253	CbGpPWpGaD
